CAR T-Cell Therapy + Ibrutinib for Chronic Lymphocytic Leukemia
Trial Summary
What is the purpose of this trial?
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you must not take targeted small molecule or kinase inhibitors within 2 weeks before a procedure called leukapheresis.
What data supports the effectiveness of the treatment CAR T-Cell Therapy + Ibrutinib for Chronic Lymphocytic Leukemia?
Research shows that using ibrutinib, a drug that helps improve T-cell function, can enhance the production and effectiveness of CAR T-cells in patients with chronic lymphocytic leukemia (CLL). This combination has shown promise in increasing the viability and function of these cells, potentially leading to better treatment outcomes for CLL patients.12345
Is CAR T-Cell Therapy + Ibrutinib safe for humans?
CAR T-cell therapies, like those from Novartis, have been approved for certain blood cancers and are generally considered safe, but they can cause side effects. Common side effects include cytokine release syndrome (a reaction that can cause fever and flu-like symptoms) and neurological effects, which are manageable with medical care.678910
What makes the CAR T-Cell Therapy + Ibrutinib treatment unique for chronic lymphocytic leukemia?
This treatment combines CAR T-cell therapy, which uses modified immune cells to target cancer, with ibrutinib, a drug that inhibits a protein important for cancer cell survival. The combination may enhance the effectiveness of CAR T-cell therapy and reduce severe side effects, offering a novel approach for patients who have not responded to other treatments.1112131415
Research Team
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Eligibility Criteria
This trial is for adults with certain blood cancers like CLL, SLL, DLBCL, and ALL. Participants must be in stable condition or partial remission after previous treatments (like ibrutinib for CLL/SLL), have not had prior CD19-directed therapy or genetically engineered cellular products, and can't have specific types of lymphoma or active CNS involvement.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase I Treatment
Dose escalation and expansion of rapcabtagene autoleucel in combination with ibrutinib for CLL/SLL and as a single agent for DLBCL and ALL
Phase II Treatment
Continuation of rapcabtagene autoleucel treatment at recommended dose for DLBCL and LBCL
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Post-study long-term follow-up for lentiviral vector safety
Treatment Details
Interventions
- Ibrutinib
- YTB323
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD